Dermatitis herpetiformis future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Dermatitis herpetiformis}} | {{Dermatitis herpetiformis}} | ||
{{CMG}} | |||
==Overview== | |||
==Future or Investigational Therapies== | |||
==References== | ==References== |
Revision as of 13:06, 14 June 2016
Dermatitis herpetiformis Microchapters |
Differentiating Dermatitis herpetiformis from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Dermatitis herpetiformis future or investigational therapies On the Web |
American Roentgen Ray Society Images of Dermatitis herpetiformis future or investigational therapies |
FDA on Dermatitis herpetiformis future or investigational therapies |
CDC on Dermatitis herpetiformis future or investigational therapies |
Dermatitis herpetiformis future or investigational therapies in the news |
Blogs on Dermatitis herpetiformis future or investigational therapies |
Risk calculators and risk factors for Dermatitis herpetiformis future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]